Shang Shunlai, Xia Jikai, He Guosen, Zheng Yan, Zhang Jian, Lu Haitao, Wang Haifeng, Li Wenge, Li Qinggang, Chen Xiangmei
Department of Nephrology, China-Japan Friendship Hospital, Beijing, China; Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases, Beijing Key Laboratory of Digital Intelligent TCM for the Prevention and Treatment of Pan-Vascular Diseases, Key Disciplines of National Administration of Traditional Chinese Medicine (zyyzdxk-2023310), Beijing, 100853, China.
Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases, Beijing Key Laboratory of Digital Intelligent TCM for the Prevention and Treatment of Pan-Vascular Diseases, Key Disciplines of National Administration of Traditional Chinese Medicine (zyyzdxk-2023310), Beijing, 100853, China; School of Clinical Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
EBioMedicine. 2025 Jun 3;117:105785. doi: 10.1016/j.ebiom.2025.105785.
With the rapid evolution of precision medicine, diagnostic, and therapeutic strategies for lupus nephritis (LN) are progressively shifting towards greater personalisation and accuracy. On the diagnostic front, the discovery and deployment of novel molecular biomarkers, together with the integration of artificial intelligence (AI) and machine learning (ML) technologies, have opened new avenues for delineating disease subtypes and forecasting treatment responses, thereby optimising clinical decision-support systems. In the therapeutic domain, innovations in targeted biologics and the precise application of diverse targeted modalities have shown promise in enhancing efficacy while reducing adverse effects. The triadic synergy of molecular biomarker breakthroughs, iterative advances in intelligent computational tools and pioneering targeted therapies is poised to usher LN in a new era of customised diagnosis and intervention.
随着精准医学的迅速发展，狼疮性肾炎（LN）的诊断和治疗策略正逐步朝着更加个性化和精准化的方向转变。在诊断方面，新型分子生物标志物的发现与应用，以及人工智能（AI）和机器学习（ML）技术的整合，为划分疾病亚型和预测治疗反应开辟了新途径，从而优化了临床决策支持系统。在治疗领域，靶向生物制剂的创新以及多种靶向治疗方式的精准应用，在提高疗效的同时减少不良反应方面显示出了前景。分子生物标志物的突破、智能计算工具的迭代进步和开创性靶向治疗的三元协同作用，有望引领LN进入定制化诊断和干预的新时代。
